Product Details
| Product Name:
BIIB068 |
CAS No.:
1798787-27-5 |
| Purity:
98.05% |
Supply Ability:
10g |
| Release date:
2026/04/21 |
Product Introduction
Bioactivity
| Name | BIIB068 |
| Description | BIIB068 is an selective, reversible and orally active BTK inhibitor (IC50 = 1 nM, Kd = 0.3 nM). BIIB068 is 400 times more selective for BTK than other kinases. |
| In vitro | BIIB068 inhibits B cell, neutrophil and monocyte activation in vitro, but not T cell responses. |
| In vivo | BIIB068 demonstrated good PK/PD correlation with in vivo EC50 = 0.16 μM based on antibody esponse, similar to in vivo WB pBTK potency in mice. BIIB068 exhibited no adverse effects in the single dose CNS and respiratory studies in rats nor in a single dose cardiovascular study in monkeys. BIIB068 was well tolerated and effective at inhibiting BTK phosphorylation in healthy subjects. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.59 mM), Sonication is recommended.
DMSO : 30 mg/mL (68.88 mM), Sonication is recommended.
|
| Keywords | TNFα | ROS | reversible | phosphorylation | Inhibitor | inhibit | FcγR | Btk | Bruton tyrosine kinase | BIIB-068 | BIIB068 | BIIB 068 | Autoimmune | anti-IgM | anti-IgD | ADME |
| Inhibitors Related | evobrutinib | (±)-Zanubrutinib | CP-547632 | CHMFL-EGFR-202 | Sunvozertinib | Ibrutinib | IBT6A | Orelabrutinib | Remibrutinib | Atuzabrutinib | Tyrosinase-IN-16 | Birelentinib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Tyrosine Kinase Inhibitor Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States